Binnopharm is a pharmaceuticals company that operates two advanced pharmaceutical plants that adhere to GMP (good vanufacturing practices) international quality standards. Binnopharm produces six dosage forms: ampoules, syringes, aerosols, pills, capsules and solutions.
Binnopharm develops and manufactures drugs for the treatment of socially important diseases (respiratory diseases, pulmonology, neurology, nephrology, infectious diseases).
Binnopharm comprises one of the largest full-cycle biopharmaceutical facilities in Russia with an area of 32,000 sq m; LLC Alium, a modern plant producing infusion solutions; and Binnopharm Distribution an in-house distributor of medicines produced both by Binnopharm/Alium and by third parties.
The company is developing original combinations, biosimilar drugs and unique medications belonging to different treatment groups: pulmonology, neurology, cardiology, gastroenterology and endocrinology.
Binnopharm has the largest GMP facilities in Russia for the production of vaccines in ampoules (up to 80m ampoules per year) and a unique, fully equipped quality control laboratory. Over the past seven years, Binnopharm has been covering the bulk of the Russian state's demand for Hepatitis B vaccine.
The company employs over 300 people, including an R&D group and a marketing and sales team, which were formed in 2015-2016.
Binnopharm's key operating objectives for 2016 include aggressive marketing and increased sales of Binnopharm products for pulmonology and neurology applications, and the registration and launch of several new products.